Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Disc Medicine Inc

IRON ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$79.23

▼ -0.18%

Market Cap $3.04B · Vol 70.87K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.04B

Mid Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

-14.29%

YoY

RSI (14)

46.53

Momentum

Beta

0.90

vs Market

52W High

$98.96

19.94% below

52W Low

$40.01

98.03% above

Volume

70.87K

Avg 121.48K

P/B

4.07

Price-to-book

ROE

-35.86%

Return on equity

Free Float

86.69%

Public shares

Shariah Compliance8 STANDARDS

✗ Disc Medicine Inc (IRON) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IRON pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.00%

+1.84%

+11.42%

+29.67%

YTD

-0.23%

+31.63%

+50.48%

+50.06%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-212,184,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-35.86%
ROA · ROIC	-32.50% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	4.07
P/FCF	N/A
EPS Growth	-14.29%
Outstanding Shares	38.39M

Technical Indicators

50-Day SMA	$77.73
200-Day SMA	$74.07
RSI (14)	46.53
Beta	0.90
52-Week High	$98.96
52-Week Low	$40.01

Volume Today	70.87K
Avg Daily Volume (30D)	121.48K
Relative Volume	0.58x
Volatility (10D)	23.29
Volatility (30D)	31.41
Free Float	86.69%

Analyst Consensus

BUY

Current Price $79.23

Mean Target $102.58

52W Low$40.01 52W High$98.96

Current

Target

$40.01 $98.96

Current Analyst target

+29.48% upside potential · 12 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00W9MJL04

ISINUS2546041011

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -2.54% RVMD Revolution Medicines Inc -0.40% ONC BeOne Medicines AG -1.22% 068270.KS Celltrion Inc +0.53% ABVX Abivax SA +0.66%

Company Profile

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.